Forsteo for glucocorticoid-induced osteoporosis

The licence for Forsteo (teriparatide) has been extended to include the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

The recommended dose of Forsteo is 20 micrograms administrated once daily by subcutaneous injection in the thigh or abdomen. The maximum total duration of treatment should be 18 months. The 18-month course should not be repeated over a patient’s lifetime.

View Forsteo drug record

Further information: Lilly

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

A careful stepwise approach is needed when reducing...

Prescribers advised not to use newer anticoagulants in patients with antiphospholipid syndrome
Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...